Laura C. Michaelis

2.3k total citations
74 papers, 917 citations indexed

About

Laura C. Michaelis is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Laura C. Michaelis has authored 74 papers receiving a total of 917 indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Hematology, 25 papers in Genetics and 20 papers in Molecular Biology. Recurrent topics in Laura C. Michaelis's work include Acute Myeloid Leukemia Research (33 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (18 papers) and Acute Lymphoblastic Leukemia research (14 papers). Laura C. Michaelis is often cited by papers focused on Acute Myeloid Leukemia Research (33 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (18 papers) and Acute Lymphoblastic Leukemia research (14 papers). Laura C. Michaelis collaborates with scholars based in United States, Canada and Malaysia. Laura C. Michaelis's co-authors include Mark J. Ratain, Olatoyosi Odenike, Srđan Verstovšek, Michael H. Kroll, David P. Steensma, Michael R. Savona, Amy E. DeZern, Guillermo Garcia‐Manero, Aram Oganesian and Hagop M. Kantarjian and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Nature reviews. Cancer.

In The Last Decade

Laura C. Michaelis

71 papers receiving 906 citations

Peers

Countries citing papers authored by Laura C. Michaelis

Since Specialization

Citations

This map shows the geographic impact of Laura C. Michaelis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura C. Michaelis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura C. Michaelis more than expected).

Fields of papers citing papers by Laura C. Michaelis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura C. Michaelis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura C. Michaelis. The network helps show where Laura C. Michaelis may publish in the future.

Co-authorship network of co-authors of Laura C. Michaelis

This figure shows the co-authorship network connecting the top 25 collaborators of Laura C. Michaelis. A scholar is included among the top collaborators of Laura C. Michaelis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura C. Michaelis. Laura C. Michaelis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia 2025 ·Leukemia ·Sameem Abedin, Guru Subramanian Guru Murthy, Mehdi Hamadani, Laura C. Michaelis, Karen-Sue Carlson, Lyndsey Runaas, (unknown), (unknown), Mary M. Chen, (unknown), (unknown), (unknown), Madhuri Vusirikala, (unknown), Ehab Atallah	4
2	A randomized Phase II trial of ASTX727 and venetoclax with or without enasidenib for newly diagnosed older adults with IDH2 mutant Acute Myeloid Leukemia: A myelomatch substudy (MM1OA-S03) 2025 ·Blood ·(unknown), Uma Borate, John L. Reagan, Richard F. Little, Steven D. Gore, Megan Othus, Anna Moseley, Manu Pandey, (unknown), Laura C. Michaelis, Geoffrey L. Uy, (unknown), Harry P. Erba	0
3	CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial 2024 ·Cancers ·Scott R. Solomon, Bayard L. Powell, (unknown), Catherine Lai, (unknown), Laura C. Michaelis, Laura F. Newell, David Sanford, (unknown), (unknown), (unknown), Stefan Faderl, Roland B. Walter	0
4	A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02 2024 ·Blood ·Jessica K. Altman, Zhuoxin Sun, Alexander E. Perl, Richard F. Little, Steven D. Gore, Laura C. Michaelis, Geoffrey L. Uy, Yasmin Abaza, Sameem Abedin, John L. Reagan, Ehab Atallah, Selina M. Luger, Mark R. Litzow	3
5	A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia 2024 ·Blood ·Naseema Gangat, James M. Foran, Anna B. Halpern, Raajit K. Rampal, Prithviraj Bose, Elizabeth O. Hexner, Moshe Talpaz, Laura C. Michaelis, (unknown), Ronan Swords, Sima Bhatt, Akshay Buch, (unknown), (unknown), Ayalew Tefferi	3
6	A Phase 1b Trial of DISC-0974, an Anti-Hemojuvelin Antibody, in Participants With Myelofibrosis and Anemia 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Naseema Gangat, James M. Foran, Anna B. Halpern, Raajit K. Rampal, Prithviraj Bose, Elizabeth O. Hexner, Moshe Talpaz, Laura C. Michaelis, (unknown), Ronan Swords, Sima Bhatt, Akshay Buch, (unknown), (unknown), Ayalew Tefferi	1
7	How I diagnose and treat thrombocytopenia in geriatric patients 2023 ·Blood ·Patrick Foy, Kenneth D. Friedman, Laura C. Michaelis	2
8	PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML 2023 ·HemaSphere ·Anand Patel, Laura C. Michaelis, Gary J. Schiller, Ronan Swords, Lawrence E. Morris, Luis A. Carvajal, Gordon L. Bray, Elizabeth Olek, Richard E. Cutler, Jorge DiMartino, Eytan M. Stein	1
9	Is there an optimal adjunct therapy to traditional cytotoxic induction? 2021 ·Best Practice & Research Clinical Haematology ·Laura C. Michaelis	1
10	Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial 2019 ·Blood ·Annette E. Hay, Sarit Assouline, Roland B. Walter, Richard F. Little, Anna Moseley, (unknown), Annie Im, James M. Foran, Jerald P. Radich, Min Fang, Megan Othus, Harry P. Erba, Laura C. Michaelis	7
11	Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML) 2018 ·Leukemia Research ·Anjali S. Advani, Hongli Li, Laura C. Michaelis, Bruno C. Medeiros, Michaela Liedtke, Alan F. List, Kristen M. O’Dwyer, Megan Othus, Harry P. Erba, Frederick R. Appelbaum	24
12	Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation 2017 ·Biology of Blood and Marrow Transplantation ·Abraham S. Kanate, Parameswaran Hari, Marcelo C. Pasquini, Alexis Visotcky, Kwang Woo Ahn, Jennifer Boyd, Guru Subramanian Guru Murthy, J. Douglas Rizzo, Wael Saber, William R. Drobyski, Laura C. Michaelis, Ehab Atallah, Karen-Sue Carlson, Anita D’Souza, Timothy S. Fenske, Aaron Cumpston, (unknown), Michael Craig, Mary M. Horowitz, Mehdi Hamadani	10
13	Recent Trends in the Incidence and Outcomes of Acute Promyelocytic Leukemia in United States 2017 ·Blood ·Guru Subramanian Guru Murthy, (unknown), Binod Dhakal, Mehdi Hamadani, Laura C. Michaelis, Ehab Atallah	1
14	Incidence and Outcomes of T-Cell Acute Lymphoblastic Leukemia (T-ALL) in United States 2017 ·Blood ·Guru Subramanian Guru Murthy, (unknown), Binod Dhakal, Mehdi Hamadani, Laura C. Michaelis, Ehab Atallah	1
15	Recent developments in the treatment of older individuals with acute myeloid leukemia 2015 ·Current Opinion in Hematology ·Laura C. Michaelis, Harry P. Erba	3
16	Trends in anemia management in lung and colon cancer patients in the US Department of Veterans Affairs, 2002–2008 2011 ·Supportive Care in Cancer ·Elizabeth Tarlov, Kevin T. Stroupe, Todd A. Lee, (unknown), (unknown), Laura C. Michaelis, Howard Ozer, (unknown), Denise M. Hynes	15
17	Rearrangements of the MLL gene are influenced by DNA secondary structure, potentially mediated by topoisomerase II binding 2009 ·Genes Chromosomes and Cancer ·(unknown), (unknown), (unknown), (unknown), (unknown), Grace A. Loredo, (unknown), Laura C. Michaelis, Amir A. Toor, Manuel O. Dı́az, Andrew Vaughan	31
18	Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial 2008 ·Leukemia & lymphoma ·Sucha Nand, John E. Godwin, Scott E. Smith, Kevin Barton, Laura C. Michaelis, Serhan Alkan, (unknown), Karen Rychlik, (unknown), Patrick J. Stiff	46
19	Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products 2008 ·Leukemia & lymphoma ·(unknown), Dorie Sher, Theodore Karrison, Partow Kebriaei, (unknown), Yanming Zhang, (unknown), Andrew Artz, Lucy A. Godley, Olatoyosi Odenike, Elizabeth Rich, Laura C. Michaelis, Michael J. Thirman, Amittha Wickrema, Koen van Besien, Richard A. Larson, Wendy Stock	6
20	Measuring response in a post-RECIST world: from black and white to shades of grey 2006 ·Nature reviews. Cancer ·Laura C. Michaelis, Mark J. Ratain	140

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact